LETTER TO JMG

A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology

R M Giusti¹, J L Rutter², P H Duray³, L S Freedman⁴, M Konichezky⁵, J Fisher-Fischbein⁶, M H Greene¹, B Maslansky⁶, A Fischbein⁷, S B Gruber⁸, G Rennert⁹, R D Ronchetti³, S M Hewitt³, J P Struewing², J Iscovich^7,*

¹ Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), Bethesda, MD, USA
² Laboratory of Population Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
³ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD
⁴ Department of Mathematics, Statistics and Computer Science, Bar Ilan University, Ramat Gan, Israel
⁵ Department of Pathology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
⁶ The International Fertility Institute, Ra’anana, Israel
⁷ Selikoff Center for Environmental Health and Human Development, Ra’anana, Israel
⁸ Division of Medical Genetics, University of Michigan, Ann Arbor, MI
⁹ Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel

Correspondence to:
Correspondence to:
Dr R Giusti
Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Executive Plaza South, Room 7024, 6120 Executive Boulevard, MSC 7231, Rockville, MD 20852-7231, USA; giusti@mail.nih.gov

Keywords: BRCA; Ashkenazi Jews; prostate cancer; pathology review

Abbreviations: PSA, prostate specific antigen

The first 150 words of the full text of this article appear below.

The magnitude of the risk of prostate cancer among Ashkenazi Jewish carriers of the common mutations in the BRCA1 and BRCA2 genes, the so-called Ashkenazi BRCA founder mutations (BRCA1 185delAG and 5382insC, and BRCA2 6174delT), remains uncertain. Two large epidemiological studies have suggested that the cumulative incidence of prostate cancer among male first degree relatives of individuals with a founder mutation may approach 30% by 80 years of age.^1,2 Smaller clinical studies have, in general, not demonstrated an increased frequency of founder mutations among Jewish men with prostate cancer.^3–6 Only one study to date has examined clinical characteristics of prostate cancer patients with founder mutations.³ In this study, the three BRCA associated tumours that were identified appeared to be associated with biologically more aggressive disease, presenting with higher PSA levels, higher Gleason scores and more advanced stage at diagnosis, than did prostate cancers diagnosed in men without mutations.

Founder . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Grindedal, E. M., Moller, P., Eeles, R., Stormorken, A. T., Bowitz-Lothe, I. M., Landro, S. M., Clark, N., Kvale, R., Shanley, S., Maehle, L. (2009). Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer. Cancer Epidemiol. Biomarkers Prev. 18: 2460-2467 [Abstract] [Full Text]  
• Agalliu, I., Gern, R., Leanza, S., Burk, R. D. (2009). Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations. Clin. Cancer Res. 15: 1112-1120 [Abstract] [Full Text]  
• Ostrander, E. A., Udler, M. S. (2008). The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited. Cancer Epidemiol. Biomarkers Prev. 17: 1843-1848 [Abstract] [Full Text]  
• Tryggvadottir, L., Vidarsdottir, L., Thorgeirsson, T., Jonasson, J. G., Olafsdottir, E. J., Olafsdottir, G. H., Rafnar, T., Thorlacius, S., Jonsson, E., Eyfjord, J. E., Tulinius, H. (2007). Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers. JNCI J Natl Cancer Inst 99: 929-935 [Abstract] [Full Text]  
• Wacholder, S., Loukissas, J. K., Hartge, P. (2007). Studies of Genes and Cancer Survival: Pieces of the Puzzle. JNCI J Natl Cancer Inst 99: 908-909 [Full Text]  
• Harlap, S., Paltiel, O., Friedlander, Y., Calderon-Margalit, R., Deutsch, L., Kleinhaus, K. R., Manor, O., Neugut, A. I., Opler, M., Perrin, M. C., Terry, M. B., Tiram, E., Yanetz, R. (2007). Prostate Cancer in Fathers With Fewer Male Offspring: the Jerusalem Perinatal Study Cohort. JNCI J Natl Cancer Inst 99: 77-81 [Abstract] [Full Text]  
• van Asperen, C J, Brohet, R M, Meijers-Heijboer, E J, Hoogerbrugge, N, Verhoef, S, Vasen, H F A, Ausems, M G E M, Menko, F H, Gomez Garcia, E B, Klijn, J G M, Hogervorst, F B L, van Houwelingen, J C, van't Veer, L J, Rookus, M A, van Leeuwen, F E, on behalf of the Netherlands Collaborative Group o, (2005). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J. Med. Genet. 42: 711-719 [Abstract] [Full Text]  
• Lorenzo Bermejo, J., Hemminki, K. (2004). Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 15: 1834-1841 [Abstract] [Full Text]  
• Zuhlke, K. A., Madeoy, J. J., Beebe-Dimmer, J., White, K. A., Griffin, A., Lange, E. M., Gruber, S. B., Ostrander, E. A., Cooney, K. A. (2004). Truncating BRCA1 Mutations Are Uncommon in a Cohort of Hereditary Prostate Cancer Families with Evidence of Linkage to 17q Markers. Clin. Cancer Res. 10: 5975-5980 [Abstract] [Full Text]  
• Kirchhoff, T., Kauff, N. D., Mitra, N., Nafa, K., Huang, H., Palmer, C., Gulati, T., Wadsworth, E., Donat, S., Robson, M. E., Ellis, N. A., Offit, K. (2004). BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews. Clin. Cancer Res. 10: 2918-2921 [Abstract] [Full Text]  
• Schaid, D. J. (2004). The complex genetic epidemiology of prostate cancer. Hum Mol Genet 13: R103-121 [Abstract] [Full Text]